Market Overview

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against CV Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm


Schall Law Firm
, a national shareholder rights litigation firm,
announces the filing of a class action lawsuit against CV Sciences, Inc.
("CV Sciences" or the "Company") (OTC: CVSI)
for violations of §§10(b) and 20(a) of the Securities Exchange Act of
1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and
Exchange Commission.

Investors who purchased the Company's shares between June 19, 2017 and
August 20, 2018, inclusive (the ''Class Period''), are encouraged to
contact the firm before October 23, 2018.

If you are a shareholder who suffered a loss, click
here to participate

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of
the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA
90067, at 424-303-1964, to discuss your rights free of charge. You can
also reach us through the firm's website at,
or by email at

The class, in this case, has not yet been certified, and until
certification occurs, you are not represented by an attorney. If you
choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading
statements to the market. CV Sciences received a non-final rejection
notice from the U.S. Patent Trademark Office (PTO) regarding its
CVSI-007 pharmaceutical product on April 27, 2017. The PTO followed the
initial non-final rejection of CVSI-007 with a final rejection on
December 14, 2017. Based on these facts, the Company's statements about
its business prospects and future operations were false and materially
misleading throughout the class period. When the market learned the
truth about CV Sciences, investors suffered damages.

the case
to recover your losses.

The Schall Law Firm represents investors around the world and
specializes in securities class action lawsuits and shareholder rights

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and rules of ethics.

View Comments and Join the Discussion!